Pharmacogenomics of β-adrenergic receptor physiology and response to β-blockade

Anesthesia and Analgesia

Volumn 113, Issue 6, 2011, Pages 1305-1318

  Von Homeyer, Peter ^a   Schwinn, Debra A ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; ATENOLOL; BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BUCINDOLOL; CYCLIC AMP; CYTOCHROME P450 2D6; DOBUTAMINE; GLUTAMINE; ISOLEUCINE; ISOPRENALINE; LEUCINE; METOPROLOL; SERINE; THREONINE; TRYPTOPHAN;

ACUTE HEART INFARCTION; ASTHMA; BETA ADRENERGIC RECEPTOR BLOCKING; BLOOD PRESSURE; BLOOD VESSEL REACTIVITY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE COURSE; ETHNIC DIFFERENCE; GENE FREQUENCY; GENETIC VARIABILITY; HEART CATHETERIZATION; HEART FAILURE; HEART FUNCTION; HEREDITY; HUMAN; HYPERTENSION; INOTROPISM; MUTATION; NONHUMAN; OBESITY; PHARMACOGENOMICS; PREOPERATIVE CARE; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; GENETIC VARIATION; HEART FAILURE; HUMANS; PHARMACOGENETICS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, ADRENERGIC, BETA;

EID: 82255162755     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/ANE.0b013e31822b887e     Document Type: Review

References (123)

1. Brodde OE. Beta-adrenoceptor blocker treatment and the cardiac beta-adrenoceptor-G-protein(s)-adenylyl cyclase system in chronic heart failure. Naunyn Schmiedebergs Arch Pharmacol 2007;374:361-72
2. Ahlquist RP. A study of the adrenotropic receptors. Am J Physiol 1948;153:586-600
3. Bylund DB, Eikenberg DC, Hieble JP, Langer SZ, Lefkowitz RJ, Minneman KP, Molinoff PB, Ruffolo RR Jr, Trendelenburg U. International Union of Pharmacology nomenclature of adrenoceptors. Pharmacol Rev 1994;46:121-36
4. Rockman HA, Koch WJ, Lefkowitz RJ. Seven-transmembranespanning receptors and heart function. Nature 2002;415: 206-12
5. Hoffmann C, Leitz MR, Oberdorf-Maass S, Lohse MJ, Klotz KN. Comparative pharmacology of human beta-adrenergic receptor subtypes-characterization of stably transfected receptors in CHO cells. Naunyn Schmiedebergs Arch Pharmacol 2004;369:151-9 (Pubitemid 38270770)
6. Kable JW, Murrin LC, Bylund DB. In vivo gene modification elucidates subtype-specific functions of alpha(2)-adrenergic receptors. J Pharmacol Exp Ther 2000;293:1-7 (Pubitemid 30180916)
7. Docherty JR. Subtypes of functional alpha1-adrenoceptor. Cell Mol Life Sci 2010;67:405-17
8. Brodde OE. Beta-adrenoceptors in cardiac disease. Pharmacol Ther 1993;60:405-30
9. Guimaraes S, Moura D. Vascular adrenoceptors: an update. Pharmacol Rev 2001;53:319-56 (Pubitemid 32476119)
10. Granneman JG, Lahners KN, Chaudhry A. Molecular cloning and expression of the rat beta 3-adrenergic receptor. Mol Pharmacol 1991;40:895-9
11. Krief S, Lonnqvist F, Raimbault S, Baude B, Van Spronsen A, Arner P, Strosberg AD, Ricquier D, Emorine LJ. Tissue distribution of beta 3-adrenergic receptor mRNA in man. J Clin Invest 1993;91:344-9 (Pubitemid 23037290)
12. Dessy C, Moniotte S, Ghisdal P, Havaux X, Noirhomme P, Balligand JL. Endothelial beta3-adrenoceptors mediate vasorelaxation of human coronary microarteries through nitric oxide and endothelium-dependent hyperpolarization. Circulation 2004;110:948-54 (Pubitemid 39128620)
13. Ursino MG, Vasina V, Raschi E, Crema F, De Ponti F. The beta3-adrenoceptor as a therapeutic target: current perspectives. Pharmacol Res 2009;59:221-34
14. Gauthier C, Langin D, Balligand JL. Beta3-adrenoceptors in the cardiovascular system. Trends Pharmacol Sci 2000;21: 426-31
15. Gauthier C, Tavernier G, Charpentier F, Langin D, Le Marec H. Functional beta3-adrenoceptor in the human heart. J Clin Invest 1996;98:556-62
16. De Boer RA, van der Harst P, van Veldhuisen DJ, van den Berg MP. Pharmacogenetics in heart failure: promises and challenges. Expert Opin Pharmacother 2009;10:1713-25
17. Rasmussen SG, Choi HJ, Rosenbaum DM, Kobilka TS, Thian FS, Edwards PC, Burghammer M, Ratnala VR, Sanishvili R, Fischetti RF, Schertler GF, Weis WI, Kobilka BK. Crystal structure of the human beta2 adrenergic G-protein-coupled receptor. Nature 2007;450:383-7 (Pubitemid 350126755)
18. Rosenbaum DM, Cherezov V, Hanson MA, Rasmussen SG, Thian FS, Kobilka TS, Choi HJ, Yao XJ, Weis WI, Stevens RC, Kobilka BK. GPCR engineering yields high-resolution structural insights into beta2-adrenergic receptor function. Science 2007;318:1266-73 (Pubitemid 350172885)
19. Stiles GL, Caron MG, Lefkowitz RJ. Beta-adrenergic receptors: biochemical mechanisms of physiological regulation. Physiol Rev 1984;64:661-743 (Pubitemid 14139089)
20. Wenzel-Seifert K, Liu HY, Seifert R. Similarities and differences in the coupling of human beta1- and beta2-adrenoceptors to Gs(alpha) splice variants. Biochem Pharmacol 2002;64:9-20 (Pubitemid 34775171)
21. Strosberg AD. Structure and function of the beta 3-adrenergic receptor. Annu Rev Pharmacol Toxicol 1997;37:421-50 (Pubitemid 27238883)
22. Rozec B, Gauthier C. beta3-adrenoceptors in the cardiovascular system: putative roles in human pathologies. Pharmacol Ther 2006;111:652-73 (Pubitemid 44137382)
23. Brodde OE, Bruck H, Leineweber K. Cardiac adrenoceptors: physiological and pathophysiological relevance. J Pharmacol Sci 2006;100:323-37 (Pubitemid 44609527)
24. Moniotte S, Vaerman JL, Kockx MM, Larrouy D, Langin D, Noirhomme P, Balligand JL. Real-time RT-PCR for the detection of beta-adrenoceptor messenger RNAs in small human endomyocardial biopsies. J Mol Cell Cardiol 2001;33:2121-33 (Pubitemid 34073055)
25. Morimoto A, Hasegawa H, Cheng HJ, Little WC, Cheng CP. Endogenous beta3-adrenoreceptor activation contributes to left ventricular and cardiomyocyte dysfunction in heart failure. Am J Physiol Heart Circ Physiol 2004;286:H2425-33 (Pubitemid 38685261)
26. Zhang ZS, Cheng HJ, Onishi K, Ohte N, Wannenburg T, Cheng CP. Enhanced inhibition of L-type Ca2+ current by beta3-adrenergic stimulation in failing rat heart. J Pharmacol Exp Ther 2005;315:1203-11 (Pubitemid 41635409)
27. Brodde OE, Leineweber K. Autonomic receptor systems in the failing and aging human heart: similarities and differences. Eur J Pharmacol 2004;500:167-76 (Pubitemid 39304006)
28. Seals DR, Esler MD. Human ageing and the sympathoadrenal system. J Physiol 2000;528:407-17
29. White M, Roden R, Minobe W, Khan MF, Larrabee P, Wollmering M, Port JD, Anderson F, Campbell D, Feldman AM. Age-related changes in beta-adrenergic neuroeffector systems in the human heart. Circulation 1994;90:1225-38 (Pubitemid 24284444)
30. El-Armouche A, Zolk O, Rau T, Eschenhagen T. Inhibitory G-proteins and their role in desensitization of the adenylyl cyclise pathway in heart failure. Cardiovasc Res 2003;60:478-87 (Pubitemid 37501105)
31. Booth JV, Landolfo KP, Chesnut LC, Bennett-Guerrero E, Gerhardt MA, Atwell DM, El-Moalem HE, Smith MS, Funk BL, Kuhn CM, Kwatra MM, Schwinn DA. Acute depression of myocardial beta-adrenergic receptor signaling during cardiopulmonary bypass: impairment of the adenylyl cyclase moiety. Duke Heart Center Perioperative Desensitization group. Anesthesiology 1998;89:602-11 (Pubitemid 28423956)
32. Gerhardt MA, Booth JV, Chesnut LC, Funk BL, el-Moalem HE, Kwatra MM, Schwinn DA. Acute myocardial betaadrenergic receptor dysfunction after cardiopulmonary bypass in patients with cardiac valve disease. Duke Heart Center Perioperative Desensitization group. Circulation 1998;98:II275-81 (Pubitemid 28512199)
33. Schwinn DA, Leone BJ, Spahn DR, Chesnut LC, Page SO, McRae RL, Liggett SB. Desensitization of myocardial betaadrenergic receptors during cardiopulmonary bypass. Evidence for early uncoupling and late downregulation. Circulation 1991;84:2559-67
34. Booth JV, Spahn DR, McRae RL, Chesnut LC, El-Moalem H, Atwell DM, Leone BJ, Schwinn DA. Esmolol improves left ventricular function via enhanced beta-adrenergic receptor signaling in a canine model of coronary revascularization. Anesthesiology 2002;97:162-9 (Pubitemid 34733936)
35. Booth JV, Ward EE, Colgan KC, Funk BL, El-Moalem H, Smith MP, Milano C, Smith PK, Newman MF, Schwinn DA. Metoprolol and coronary artery bypass grafting surgery: does intraoperative metoprolol attenuate acute beta-adrenergic receptor desensitization during cardiac surgery? Anesth Analg 2004;98:1224-31 (Pubitemid 38525571)
36. Poldermans D, Boersma E, Bax JJ, Thomson IR, van de Ven LL, Blankensteijn JD, Baars HF, Yo TI, Trocino G, Vigna C, Roelandt JR, van Urk H. The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery. Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography Study group. N Engl J Med 1999;341:1789-94
37. Mangano DT, Layug EL, Wallace A, Tateo I. Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery. Multicenter Study of Perioperative Ischemia Research group. N Engl J Med 1996;335:1713-20 (Pubitemid 26399345)
38. Poldermans D, Bax JJ, Boersma E, De Hert S, Eeckhout E, Fowkes G, Gorenek B, Hennerici MG, Lung B, Kelm M, Kjeldsen KP, Kristensen SD, Lopez-Sendon J, Pelosi P, Philippe F, Pierard L, Ponikowski P, Schmid JP, Sellevold OF, Sicari R, Van den Berghe G, Vermassen F, Hoeks SE, Vanhorebeek I. Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in noncardiac surgery: the Task Force for Preoperative Cardiac Risk Assessment and Perioperative Cardiac Management in Noncardiac Surgery of the European Society of Cardiology (ESC) and European Society of Anaesthesiology (ESA). Eur Heart J 2009;30:2769-812
39. Fleischmann KE, Beckman JA, Buller CE, Calkins H, Fleisher LA, Freeman WK, Froehlich JB, Kasper EK, Kersten JR, Robb JF, Valentine RJ. 2009 ACCF/AHA focused update on perioperative beta blockade. J Am Coll Cardiol 2009;54:2102-28
40. Devereaux PJ, Yang H, Yusuf S, Guyatt G, Leslie K, Villar JC, Xavier D, Chrolavicius S, Greenspan L, Pogue J, Pais P, Liu L, Xu S, Malaga G, Avezum A, Chan M, Montori VM, Jacka M, Choi P. Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. Lancet 2008;371:1839-47
41. Talati R, Reinhart KM, White CM, Phung OJ, Sedrakyan A, Kluger J, Coleman CI. Outcomes of perioperative betablockade in patients undergoing noncardiac surgery: a metaanalysis. Ann Pharmacother 2009;43:1181-8
42. Bangalore S, Wetterslev J, Pranesh S, Sawhney S, Gluud C, Messerli FH. Perioperative beta blockers in patients having non-cardiac surgery: a meta-analysis. Lancet 2008;372:1962-76
43. Taylor MR. Pharmacogenetics of the human beta-adrenergic receptors. Pharmacogenomics J 2007;7:29-37 (Pubitemid 46322077)
44. Leineweber K, Heusch G. Beta 1- and beta 2-adrenoceptor polymorphisms and cardiovascular diseases. Br J Pharmacol 2009;158:61-9
45. Liggett SB. Pharmacogenomics of beta1-adrenergic receptor polymorphisms in heart failure. Heart Fail Clin 2010;6:27-33
46. Brodde OE. Beta1- and beta2-adrenoceptor polymorphisms and cardiovascular diseases. Fundam Clin Pharmacol 2008;22: 107-25
47. McGraw DW, Forbes SL, Kramer LA, Liggett SB. Polymorphisms of the 5′ leader cistron of the human beta2- adrenergic receptor regulate receptor expression. J Clin Invest 1998;102:1927-32 (Pubitemid 29001838)
48. Leineweber K. Beta-adrenergic receptor polymorphism in human cardiovascular disease. Ann Med 2004;36(Suppl 1):64-9 (Pubitemid 38669926)
49. Brodde OE, Leineweber K. Beta2-adrenoceptor gene polymorphisms. Pharmacogenet Genomics 2005;15:267-75
50. Gjesing AP, Andersen G, Borch-Johnsen K, Jorgensen T, Hansen T, Pedersen O. Association of the beta3-adrenergic receptor Trp64Arg polymorphism with common metabolic traits: studies of 7605 middle-aged White people. Mol Genet Metab 2008;94:90-7
51. Leineweber K, Buscher R, Bruck H, Brodde OE. Betaadrenoceptor polymorphisms. Naunyn Schmiedebergs Arch Pharmacol 2004;369:1-22
52. McNamara DM. Emerging role of pharmacogenomics in heart failure. Curr Opin Cardiol 2008;23:261-8 (Pubitemid 351489330)
53. Shin J, Johnson JA. Pharmacogenetics of beta-blockers. Pharmacotherapy 2007;27:874-87
54. Azuma J, Nonen S. Chronic heart failure: beta-blockers and pharmacogenetics. Eur J Clin Pharmacol 2009;65:3-17
55. Shin J, Johnson JA. Beta-blocker pharmacogenetics in heart failure. Heart Fail Rev 2010;15:187-96
56. Liggett SB, Wagoner LE, Craft LL, Hornung RW, Hoit BD, McIntosh TC, Walsh RA. The Ile164 beta2-adrenergic receptor polymorphism adversely affects the outcome of congestive heart failure. J Clin Invest 1998;102:1534-9 (Pubitemid 28492220)
57. Turki J, Lorenz JN, Green SA, Donnelly ET, Jacinto M, Liggett SB. Myocardial signaling defects and impaired cardiac function of a human beta 2-adrenergic receptor polymorphism expressed in transgenic mice. Proc Natl Acad Sci USA 1996;93:10483-8
58. Biolo A, Clausell N, Santos KG, Salvaro R, Ashton-Prolla P, Borges A, Rohde LE. Impact of beta1-adrenergic receptor polymorphisms on susceptibility to heart failure, arrhythmogenesis, prognosis, and response to beta-blocker therapy. Am J Cardiol 2008;102:726-32
59. Mialet Perez J, Rathz DA, Petrashevskaya NN, Hahn HS, Wagoner LE, Schwartz A, Dorn GW, Liggett SB. Beta 1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure. Nat Med 2003;9:1300-5 (Pubitemid 37279854)
60. Petersen M, Andersen JT, Hjelvang BR, Broedbaek K, Afzal S, Nyegaard M, Borglum AD, Stender S, Kober L, Torp-Pedersen C, Poulsen HE. Association of beta-adrenergic receptor polymorphisms and mortality in carvedilol-treated chronic heartfailure patients. Br J Clin Pharmacol 2011;71:556-65
61. Piscione F, Iaccarino G, Galasso G, Cipolletta E, Rao MA, Brevetti G, Piccolo R, Trimarco B, Chiariello M. Effects of Ile164 polymorphism of beta2-adrenergic receptor gene on coronary artery disease. J Am Coll Cardiol 2008;52:1381-8
62. Barbato E, Berger A, Delrue L, Van Durme F, Manoharan G, Boussy T, Heyndrickx GR, De Bruyne B, Ciampi Q, Vanderheyden M, Wijns W, Bartunek J. GLU-27 variant of beta2- adrenergic receptor polymorphisms is an independent risk factor for coronary atherosclerotic disease. Atherosclerosis 2007;194:e80-6 (Pubitemid 47513088)
63. Zee RY, Cook NR, Reynolds R, Cheng S, Ridker PM. Haplotype analysis of the beta2 adrenergic receptor gene and risk of myocardial infarction in humans. Genetics 2005;169:1583-7 (Pubitemid 40547466)
64. Schurks M, Kurth T, Ridker PM, Buring JE, Zee RY. Association between polymorphisms in the beta2-adrenergic receptor gene with myocardial infarction and ischaemic stroke in women. Thromb Haemost 2009;101:351-8
65. Leineweber K, Bogedain P, Wolf C, Wagner S, Weber M, Jakob HG, Heusch G, Philipp T, Brodde OE. In patients chronically treated with metoprolol, the demand of inotropic catecholamine support after coronary artery bypass grafting is determined by the Arg389Gly-beta 1-adrenoceptor polymorphism. Naunyn Schmiedebergs Arch Pharmacol 2007; 375:303-9 (Pubitemid 46945336)
66. Lanfear DE, Jones PG, Marsh S, Cresci S, McLeod HL, Spertus JA. Beta2-adrenergic receptor genotype and survival among patients receiving beta-blocker therapy after an acute coronary syndrome. JAMA 2005;294:1526-33 (Pubitemid 41362690)
67. Metra M, Covolo L, Pezzali N, Zaca V, Bugatti S, Lombardi C, Bettari L, Romeo A, Gelatti U, Giubbini R, Donato F, Dei Cas L. Role of beta-adrenergic receptor gene polymorphisms in the long-term effects of beta-blockade with carvedilol in patients with chronic heart failure. Cardiovasc Drugs Ther 2010;24:49-60
68. Rau T, Heide R, Bergmann K, Wuttke H, Werner U, Feifel N, Eschenhagen T. Effect of the CYP2D6 genotype on metoprolol metabolism persists during long-term treatment. Pharmacogenetics 2002;12:465-72 (Pubitemid 34913529)
69. Rau T, Wuttke H, Michels LM, Werner U, Bergmann K, Kreft M, Fromm MF, Eschenhagen T. Impact of the CYP2D6 genotype on the clinical effects of metoprolol: a prospective longitudinal study. Clin Pharmacol Ther 2009;85:269-72
70. Goryachkina K, Burbello A, Boldueva S, Babak S, Bergman U, Bertilsson L. CYP2D6 is a major determinant of metoprolol disposition and effects in hospitalized Russian patients treated for acute myocardial infarction. Eur J Clin Pharmacol 2008;64:1163-73
71. Moore JD, Mason DA, Green SA, Hsu J, Liggett SB. Racial differences in the frequencies of cardiac beta(1)-adrenergic receptor polymorphisms: analysis of c145A>G and c1165G>C. Hum Mutat 1999;14:271
72. Small KM, McGraw DW, Liggett SB. Pharmacology and physiology of human adrenergic receptor polymorphisms. Annu Rev Pharmacol Toxicol 2003;43:381-411 (Pubitemid 37372647)
73. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 2001;344:1659-67
74. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;353:2001-7
75. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999;353:9-13
76. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Castaigne A, Roecker EB, Schultz MK, DeMets DL. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001;344:1651-8 (Pubitemid 32479962)
77. Packer M, Fowler MB, Roecker EB, Coats AJ, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Staiger C, Holcslaw TL, Amann-Zalan I, DeMets DL. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 2002;106:2194-9 (Pubitemid 35222212)
78. Ishizawar D, Yancy C. Racial differences in heart failure therapeutics. Heart Fail Clin 2010;6:65-74
79. Goldstein S. Beta blocker therapy in African American patientswith heart failure. Heart Fail Rev 2004;9:161-7 (Pubitemid 39485477)
80. Yancy CW, Laskar S, Eichhorn E. The use of beta-adrenergic receptor antagonists in the treatment of African Americans with heart failure. Congest Heart Fail 2004;10:34-7
81. Andreka P, Aiyar N, Olson LC, Wei JQ, Turner MS, Webster KA, Ohlstein EH, Bishopric NH. Bucindolol displays intrinsic sympathomimetic activity in human myocardium. Circulation 2002;105:2429-34 (Pubitemid 34556397)
82. Shekelle PG, Rich MW, Morton SC, Atkinson CS, Tu W, Maglione M, Rhodes S, Barrett M, Fonarow GC, Greenberg B, Heidenreich PA, Knabel T, Konstam MA, Steimle A, Warner Stevenson L. Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. J Am Coll Cardiol 2003;41:1529-38 (Pubitemid 36543372)
83. Kurnik D, Li C, Sofowora GG, Friedman EA, Muszkat M, Xie HG, Harris PA, Williams SM, Nair UB, Wood AJ, Stein CM. Beta-1-adrenoceptor genetic variants and ethnicity independently affect response to beta-blockade. Pharmacogenet Genomics 2008;18:895-902
84. Cresci S, Kelly RJ, Cappola TP, Diwan A, Dries D, Kardia SL, Dorn GW, second. Clinical and genetic modifiers of long-term survival in heart failure. J Am Coll Cardiol 2009;54:432-44
85. Weir TD, Mallek N, Sandford AJ, Bai TR, Awadh N, Fitzgerald JM, Cockcroft D, James A, Liggett SB, Pare PD. Beta2-adrenergic receptor haplotypes in mild, moderate and fatal/near fatal asthma. Am J Respir Crit Care Med 1998;158:787-91 (Pubitemid 28449441)
86. Sears MR, Taylor DR, Print CG, Lake DC, Li QQ, Flannery EM, Yates DM, Lucas MK, Herbison GP. Regular inhaled betaagonist treatment in bronchial asthma. Lancet 1990;336:1391-6
87. Spitzer WO, Suissa S, Ernst P, Horwitz RI, Habbick B, Cockcroft D, Boivin JF, McNutt M, Buist AS, Rebuck AS. The use of beta-agonists and the risk of death and near death from asthma. N Engl J Med 1992;326:501-6
88. Bai TR, Mak JC, Barnes PJ. A comparison of beta-adrenergic receptors and in vitro relaxant responses to isoproterenol in asthmatic airway smooth muscle. Am J Respir Cell Mol Biol 1992;6:647-51
89. Turki J, Pak J, Green SA, Martin RJ, Liggett SB. Genetic polymorphisms of the beta 2-adrenergic receptor in nocturnal and nonnocturnal asthma. Evidence that Gly16 correlates with the nocturnal phenotype. J Clin Invest 1995;95:1635-41
90. Hall IP, Wheatley A, Wilding P, Liggett SB. Association of Glu 27 beta 2-adrenoceptor polymorphism with lower airway reactivity in asthmatic subjects. Lancet 1995;345:1213-4
91. Israel E, Chinchilli VM, Ford JG, Boushey HA, Cherniack R, Craig TJ, Deykin A, Fagan JK, Fahy JV, Fish J, Kraft M, Kunselman SJ, Lazarus SC, Lemanske RF Jr, Liggett SB, Martin RJ, Mitra N, Peters SP, Silverman E, Sorkness CA, Szefler SJ, Wechsler ME, Weiss ST, Drazen JM. Use of regularly scheduled albuterol treatment in asthma: genotypestratified, randomised, placebo-controlled cross-over trial. Lancet 2004;364:1505-12 (Pubitemid 39410416)
92. Wechsler ME, Lehman E, Lazarus SC, Lemanske RF Jr, Boushey HA, Deykin A, Fahy JV, Sorkness CA, Chinchilli VM, Craig TJ, DiMango E, Kraft M, Leone F, Martin RJ, Peters SP, Szefler SJ, Liu W, Israel E. Beta-adrenergic receptor polymorphisms and response to salmeterol. Am J Respir Crit Care Med 2006;173:519-26
93. Bleecker ER, Nelson HS, Kraft M, Corren J, Meyers DA, Yancey SW, Anderson WH, Emmett AH, Ortega HG. Beta2- receptor polymorphisms in patients receiving salmeterol with or without fluticasone propionate. Am J Respir Crit Care Med 2010;181:676-87
94. Wechsler ME, Kunselman SJ, Chinchilli VM, Bleecker E, Boushey HA, Calhoun WJ, Ameredes BT, Castro M, Craig TJ, Denlinger L, Fahy JV, Jarjour N, Kazani S, Kim S, Kraft M, Lazarus SC, Lemanske RF, Jr., Markezich A, Martin RJ, Permaul P, Peters SP, Ramsdell J, Sorkness CA, Sutherland ER, Szefler SJ, Walter MJ, Wasserman SI, Israel E. Effect of beta2-adrenergic receptor polymorphism on response to longacting beta2 agonist in asthma (LARGE trial): a genotypestratified, randomised, placebo-controlled, crossover trial. Lancet 2009;374:1754-64
95. Kim WJ, OH YM, Sung J, Kim TH, Huh JW, Jung H, Lee JH, Kim EK, Lee SM, Lee S, Lim SY, Shin TR, Yoon HI, Kwon SY, Lee SD. Lung function response to 12-week treatment with combined inhalation of long-acting beta2 agonist and glucocorticoid according to ADRB2 polymorphism in patients with chronic obstructive pulmonary disease. Lung 2008;186:381-6
96. Carroll CL, Stoltz P, Schramm CM, Zucker AR. Beta2- adrenergic receptor polymorphisms affect response to treatment in children with severe asthma exacerbations. Chest 2009;135:1186-92
97. Martin AC, Zhang G, Rueter K, Khoo SK, Bizzintino J, Hayden CM, Geelhoed GC, Goldblatt J, Laing IA, Le Souef PN. Beta2-adrenoceptor polymorphisms predict response to beta2-agonists in children with acute asthma. J Asthma 2008;45:383-8 (Pubitemid 351882719)
98. Wang WC, Mihlbachler KA, Brunnett AC, Liggett SB. Targeted transgenesis reveals discrete attenuator functions of GRK and PKA in airway beta2-adrenergic receptor physiologic signaling. Proc Natl Acad Sci USA 2009;106:15007-12
99. Wang WC, Mihlbachler KA, Bleecker ER, Weiss ST, Liggett SB. A polymorphism of G-protein coupled receptor kinase5 alters agonist-promoted desensitization of beta2-adrenergic receptors. Pharmacogenet Genomics 2008;18:729-32
100. Hoit BD, Suresh DP, Craft L, Walsh RA, Liggett SB. Beta2- adrenergic receptor polymorphisms at amino acid 16 differentially influence agonist-stimulated blood pressure and peripheral blood flow in normal individuals. Am Heart J 2000;139:537-42 (Pubitemid 30149205)
101. Cockcroft JR, Gazis AG, Cross DJ, Wheatley A, Dewar J, Hall IP, Noon JP. Beta(2)-adrenoceptor polymorphism determines vascular reactivity in humans. Hypertension 2000;36: 371-5
102. Kotanko P, Binder A, Tasker J, DeFreitas P, Kamdar S, Clark AJL, Skrabal F, Caulfield M. Essential hypertension in African Caribbean associates with a variant of the beta(2)- adrenoceptor. Hypertension 1997;30:773-6 (Pubitemid 27441100)
103. Pacanowski MA, Gong Y, Cooper-Dehoff RM, Schork NJ, Shriver MD, Langaee TY, Pepine CJ, Johnson JA. Betaadrenergic receptor gene polymorphisms and beta-blocker treatment outcomes in hypertension. Clin Pharmacol Ther 2008;84:715-21
104. Iwamoto Y, Ohishi M, Yuan M, Tatara Y, Kato N, Takeya Y, Onishi M, Maekawa Y, Kamide K, Rakugi H. Beta-adrenergic receptor gene polymorphism is a genetic risk factor for cardiovascular disease: a cohort study with hypertensive patients. Hypertens Res 2011;34:573-7
105. Yuan H, Huang Z, Yang G, Lv H, Sang H, Yao Y. Effects of polymorphism of the beta(1) adrenoreceptor and CYP2D6 on the therapeutic effects of metoprolol. J Int Med Res 008;36:1354-62
106. Large V, Hellstrom L, Reynisdottir S, Lonnqvist F, Eriksson P, Lannfelt L, Arner P. Human beta-2 adrenoceptor gene polymorphisms are highly frequent in obesity and associate with altered adipocyte beta-2 adrenoceptor function. J Clin Invest 1997;100:3005-13 (Pubitemid 28022837)
107. Hoffstedt J, Iliadou A, Pedersen NL, Schalling M, Arner P. The effect of the beta(2) adrenoceptor gene Thr164Ile polymorphism on human adipose tissue lipolytic function. Brit J Pharmacol 2001;133:708-12 (Pubitemid 32642876)
108. Yamada K, Ishiyama-Shigemoto S, Ichikawa F, Yuan XH, Koyanagi A, Koyama W, Nonaka K. Polymorphism in the 5′- leader cistron of the beta(2)-adrenergic receptor gene associated with obesity and type 2 diabetes. J Clin Endocr Metab 1999;84:1754-7 (Pubitemid 30644288)
109. Nonen S, Yamamoto I, Liu JM, Maeda M, Motomura T, Igarashi T, Fujio Y, Azuma J. Adrenergic beta(1) receptor polymorphism (Ser49Gly) is associated with obesity in type II diabetic patients. Biol Pharm Bull 2008;31:295-8 (Pubitemid 351198410)
110. Kurokawa N, Nakai K, Kameo S, Liu ZM, Satoh H. Association of BMI with the beta3-adrenergic receptor gene polymorphism in Japanese: meta-analysis. Obes Res 2001;9:741-5 (Pubitemid 33603888)
111. Ellsworth DL, Coady SA, Chen W, Srinivasan SR, Boerwinkle E, Berenson GS. Interactive effects between polymorphisms in the beta-adrenergic receptors and longitudinal changes in obesity. Obes Res 2005;13:519-26
112. Widen E, Lehto M, Kanninen T, Walston J, Shuldiner AR, Groop LC. Association of a polymorphism in the beta 3-adrenergic-receptor gene with features of the insulin resistance syndrome in Finns. N Engl J Med 1995;333:348-51
113. Masuo K. Roles of beta2- and beta3-adrenoceptor polymorphisms in hypertension and metabolic syndrome. Int J Hypertens 2010;2010:832821
114. Kim NS, Lee IO, Lee MK, Lim SH, Choi YS, Kong MH. The effects of beta2 adrenoceptor gene polymorphisms on pressor response during laryngoscopy and tracheal intubation. Anaesthesia 2002;57:227-32
115. Smiley RM, Blouin JL, Negron M, Landau R. beta2- adrenoceptor genotype affects vasopressor requirements during spinal anesthesia for cesarean delivery. Anesthesiology 2006;104:644-50
116. Zaugg M, Bestmann L, Wacker J, Lucchinetti E, Boltres A, Schulz C, Hersberger M, Kalin G, Furrer L, Hofer C, Blumenthal S, Muller A, Zollinger A, Spahn DR, Borgeat A. Adrenergic receptor genotype but not perioperative bisoprolol therapy may determine cardiovascular outcome in at-risk patients undergoing surgery with spinal block: the Swiss Beta Blocker in Spinal Anesthesia (BBSA) study: a double-blinded, placebo-controlled, multicenter trial with 1-year follow-up. Anesthesiology 2007;107:33-44 (Pubitemid 46987817)
117. Bengtsson K, Melander O, Orho-Melander M, Lindblad U, Ranstam J, Rastam L, Groop L. Polymorphism in the beta(1)- adrenergic receptor gene and hypertension. Circulation 2001;104:187-90 (Pubitemid 32655836)
118. Iwai C, Akita H, Kanazawa K, Shiga N, Terashima M, Matsuda Y, Takai E, Miyamoto Y, Shimizu M, Kajiya T, Hayashi T, Yokoyama M. Arg389Gly polymorphism of the human beta1-adrenergic receptor in patients with nonfatal acute myocardial infarction. Am Heart J 2003;146:106-9 (Pubitemid 36851307)
119. Akhter SA, DSouza KM, Petrashevskaya NN, Mialet-Perez J, Liggett SB. Myocardial beta1-adrenergic receptor polymorphisms affect functional recovery after ischemic injury. Am J Physiol Heart Circ Physiol 2006;290:H1427-32
120. Sandilands AJ, OShaughnessy KM, Brown MJ. Greater inotropic and cyclic AMP responses evoked by noradrenaline through Arg389 beta 1-adrenoceptors versus Gly389 beta 1-adrenoceptors in isolated human atrial myocardium. Br J Pharmacol 2003;138:386-92 (Pubitemid 36188600)
121. Bruck H, Leineweber K, Temme T, Weber M, Heusch G, Philipp T, Brodde OE. The Arg389Gly beta1-adrenoceptor polymorphism and catecholamine effects on plasma-renin activity. J Am Coll Cardiol 2005;46:2111-5 (Pubitemid 41713600)
122. Badgett RG, Lawrence VA, Cohn SL. Variations in pharmacology of beta-blockers may contribute to heterogeneous results in trials of perioperative beta-blockade. Anesthesiology 2010;113:585-92
123. DeGeorge BR Jr, Koch WJ. Beta blocker specificity: a building block toward personalized medicine. J Clin Invest 2007;117:86-9 (Pubitemid 46048454)